Ionis Pharmaceuticals/$IONS
1D1W1MYTD1Y5YMAX
Capital at risk
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
- Ticker
- $IONS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,480
- Headquarters
- Carlsbad, United States
- Website
- www.ionis.com
IONS Metrics
BasicAdvanced
$7.5B
-
-$3.46
0.40
-
Price and volume
Market cap
$7.5B
Beta
0.4
52-week high
$86.74
52-week low
$44.66
Average daily volume
3M
Financial strength
Current ratio
7.893
Quick ratio
6.69
Long term debt to equity
4.949
Total debt to equity
4.978
Interest coverage (TTM)
-6.06%
Profitability
EBITDA (TTM)
-579.485
Gross margin (TTM)
-5.09%
Net profit margin (TTM)
-64.73%
Operating margin (TTM)
-68.00%
Effective tax rate (TTM)
-0.58%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-12.42%
Return on equity (TTM)
-105.54%
Valuation
Price to revenue (TTM)
8.368
Price to book
16.88
Price to tangible book (TTM)
16.88
Price to free cash flow (TTM)
-12.886
Free cash flow yield (TTM)
-7.76%
Free cash flow per share (TTM)
-3.48
Growth
Revenue change (TTM)
-7.41%
Earnings per share change (TTM)
101.02%
3-year revenue growth (CAGR)
11.48%
10-year revenue growth (CAGR)
17.38%
3-year earnings per share growth (CAGR)
16.89%
10-year earnings per share growth (CAGR)
6.27%
What the Analysts think about IONS
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
Analyst projections of the future price of Ionis Pharmaceuticals stock.
Bulls say / Bears say
Commercial revenue rose 15% year on year in the second quarter and 27% in the first half of 2026. Tryngolza’s U.S. launch and Dawnzera’s growth are beginning to reduce Ionis’s dependence on licensing income. (SEC)
The FDA approved Zanvastro as the first treatment for Alexander disease and the first therapy to target its underlying protein build-up. Its broad paediatric and adult approval, plus a Rare Pediatric Disease Priority Review Voucher, supports Ionis’s first independent neurology launch. (FDA)
Ionis has several further catalysts beyond its current products: bepirovirsen is approaching a regulatory decision for chronic hepatitis B, while the Phase III Angelman syndrome programme has completed enrolment. Positive outcomes could add partnered revenue and extend the company’s commercial growth runway. (The Motley Fool)
Pelacarsen, a major partnered cardiovascular opportunity, failed to reduce cardiovascular events in its 8,323-patient Phase III trial, despite lowering Lp(a). This removes a significant potential source of milestones and royalties. (Novartis)
Eplontersen also missed the primary efficacy endpoint in the Phase III CARDIO-TTRansform study for ATTR cardiomyopathy. Two high-profile cardiovascular setbacks in quick succession raise doubts about the value of Ionis’s partnered pipeline. (The Motley Fool)
Ionis remains loss-making while funding several launches and clinical programmes: second-quarter operating expenses rose to $370 million and cash, cash equivalents and short-term investments fell to $2.055 billion by June. Continued spending makes the 2028 cash-flow breakeven target dependent on strong commercial execution. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
IONS Financial Performance
Revenues and expenses
IONS Earnings Performance
Company profitability
Upcoming events
No upcoming events
IONS News
AllArticlesVideos
Funds containing IONS
AllUSDGBPEUR
Fund name | Fund size | $IONS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.53% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.53% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.15% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.15% |
Amundi S&P 500£500G | £6.6B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.